4 news items
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
the immune response.
About CSL
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
ARCT
11 Mar 24
their response to recent developments related to Arcturus Therapeutics. This offers insight into analysts' perspectives on the current state of the company
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
ARCT
7 Mar 24
induced a stronger, broader, and more durable immune response compared to an approved conventional mRNA vaccine
- Prev
- 1
- Next